Novalar Pharmaceuticals, Inc. Plans Shutdown Following Sale of OraVerse to Septodont, to Cut 12 Jobs
Xconomy -- It turns out that Novalar Pharmaceuticals’ decision to sell OraVerse, its dental anesthesia reversal agent, was only half the story.